Last reviewed · How we verify
Uncomplicated Urinary Tract Infections — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Test formulation (Treatment A) | test-formulation-treatment-a | Pfizer | Enzyme inhibitor | Specific enzyme | Not yet determined | |
| Blujepa | GEPOTIDACIN | Glaxosmithkline | 2025-01-01 | |||
| Various | various | Pfizer | Antibiotic | Not specified |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Uncomplicated Urinary Tract Infections
- Glaxosmithkline · 1 drug in Uncomplicated Urinary Tract Infections
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Uncomplicated Urinary Tract Infections:
- Uncomplicated Urinary Tract Infections treatment updates — RSS
- Uncomplicated Urinary Tract Infections treatment updates — Atom
- Uncomplicated Urinary Tract Infections treatment updates — JSON
Cite this brief
Drug Landscape (2026). Uncomplicated Urinary Tract Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/uncomplicated-urinary-tract-infections. Accessed 2026-06-11.
Related
- Uncomplicated Urinary Tract Infections full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing